NIKKEI 225
40,502.79 +428.10 (+1.07%) HANG SENG
18,014.26 +245.12 (+1.38%) CRUDE OIL
83.22 +0.41 (+0.50%) GOLD FUTURES
2,341.40 +8.00 (+0.34%) DOW
39,331.85 +162.33 (+0.41%) Bitcoin GBP
47,913.13 -1,818.97 (-3.66%)
RFL Aug 2024 2.500 call
- Simply Wall St.
Rafael Holdings Third Quarter 2024 Earnings: US$1.36 loss per share (vs US$0.061 loss in 3Q 2023)
Rafael Holdings ( NYSE:RFL ) Third Quarter 2024 Results Key Financial Results Net loss: US$32.4m (loss widened by...
- GlobeNewswire
Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results
Strategically focused on generating shareholder value by advancing our portfolio and identifying attractive investment opportunities with substantive upside potentialNEWARK, N.J., June 14, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the third quarter and the first nine months of fiscal 2024 ended April 30, 2024. “During fiscal 2024, we have continued to develop our existing portfolio while actively evaluating opportunities for strategic in
- Business Wire
Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1
GAINESVILLE, Fla., May 30, 2024--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the last patient has been enrolled in the Company’s pivotal Phase 3 study ("TransportNPC™") evaluating Trappsol® Cyclo™ for the treatment of systemic and neurological symptoms of Niemann-Pick Disease Type
